Analysis of the relation between adverse events and overall …
May 15, 2023 · Many trials supported pembrolizumab as a first-line monotherapy to significantly improve overall survival (OS) in selected patients with previously untreated metastatic …
Retrospective analysis of pembrolizumab-related adverse reactions …
May 22, 2025 · Pembrolizumab is a monoclonal antibody targeting the immune checkpoint programmed death receptor 1 (PD-1) [].In the field of cancer treatment, pembrolizumab has …
Merck’s Investigational Subcutaneous Pembrolizumab With ...
Mar 27, 2025 · In the 3475A-D77 trial, subcutaneous pembrolizumab, administered every six weeks with a median injection time of two minutes (4.8 mL) along with chemotherapy, …
the investigator’s choice of cytotoxic chemotherapy as rst-line therapy in patients with advanced NSCLC and a PD-L1 TPS of 50% or greater. Based on this trial’s results, pembrolizumab was …
Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With …
Feb 26, 2024 · Pembrolizumab plus chemotherapy is one of the recommended first-line treatment options in patients with metastatic NSCLC with PD-L1 TPS less than 1%. 3–7 Despite …
Pembrolizumab With or Without Maintenance Olaparib for …
Feb 1, 2025 · Pembrolizumab, an anti‒programmed cell death protein 1 (PD-1) monoclonal antibody, improves overall survival (OS) in patients with advanced or metastatic NSCLC both …
Association between the efficacy and immune-related adverse …
Oct 6, 2022 · The combination of immune-checkpoint inhibitors with chemotherapy has become the standard of treatment for non-small cell lung cancer (NSCLC) patients. However, the …
New Data Evaluating KEYTRUDA® (pembrolizumab) in Combination ... - Merck
Jun 4, 2016 · without, in non-small cell lung cancer (NSCLC) including chemotherapy in previously untreated patients with NSCLC; the study showed overall response rates (ORR) …
Risk factors of immune-related endocrine toxicities in non-small …
Mar 13, 2025 · Background Pembrolizumab has been approved as a first-line treatment for non-small cell lung cancer (NSCLC) patients. However, a percentage of patients discontinue …
Pembrolizumab as first-line treatment for advanced NSCLC in …
Sep 1, 2023 · Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes ... Non-small cell lung cancer …
Pembrolizumab in Combination With Chemotherapy in First-Line …
Feb 25, 2019 · Pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel was approved as first-line treatment of metastatic squamous NSCLC. The …
Risk factors for severe immune-related adverse events after first-line …
Oct 13, 2022 · Pembrolizumab treatment is associated with a favorable prognosis in patients with non-small-cell lung cancer (NSCLC). Here, we investigated the associations among pre …
24P: 5-year real-world outcomes with first-line (1L) pembrolizumab …
In clinical trials, 1L pembrolizumab + chemotherapy in patients (pts) with non-squamous (NSQ) and squamous (SQ) metastatic NSCLC has demonstrated durable, clinically meaningful …
Pembrolizumab as first-line therapy for patients with PD-L1 …
Pembrolizumab improved survival as first- and second-line therapy compared with chemotherapy in patients with highly programmed death ligand 1 (PD-L1) expressing advanced non-small …
Immune-related Adverse Events of Pembrolizumab in a Large …
Nov 1, 2020 · We evaluated the irAE profile within the study population of a real-world multicenter retrospective study evaluating patients with metastatic NSCLC with a PD-L1 expression ≥ …
(NEW Update) Pembrolizumab in NSCLC - JNCCN 360
Updates in First-Line Treatment. Pembrolizumab was first approved in 2015 for second-line treatment of patients with metastatic non–small cell lung cancer ... The adverse reactions …
Randomized phase 2 trial of pembrolizumab alone or in …
May 1, 2025 · Patients with advanced NSCLC and an Eastern Cooperative Oncology Group performance status (PS) of 2 were randomized to single-agent pembrolizumab at 200 mg …
Clinical benefit of pembrolizumab in treatment of first line non …
May 19, 2023 · Pembrolizumab has become an integral first line therapeutic agent for non-small cell lung cancer (NSCLC), but its potential predictive role in clinical and molecular …
P42-2 Systematic review of pembrolizumab vs. chemotherapy in …
The objective of this systematic review is to compare the efficacy and safety of pembrolizumab and chemotherapy as first-line treatments for Non-Small Cell Lung Cancer (NSCLC). We …
Five-year efficacy and safety of pembrolizumab as first-line …
Mar 1, 2025 · The enrollment period for this cohort was from February 2017 (the date of approval of first-line pembrolizumab for non-small cell lung cancer [NSCLC] in patients with PD-L1 TPS …